Overview

Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

Phase:

Phase 4

Details

Lead Sponsor:

Guangdong General Hospital
Guangdong Provincial People's Hospital

Treatments:

Fluvoxamine
Methylphenidate